Kukje Pharma: Q1 2026 Sales +6%, Net Profit Up, Operating Profit Down; 30 Won Dividend

Consolidated Q1 2026 revenue KRW 43.98bn (+6% YoY), operating profit KRW 1.97bn (-14.5%), net profit KRW 2.14bn (+15.4%)
Cash dividend of KRW 30 per share (total KRW 635mn) for FY2025 approved and paid on March 26, 2026
Total borrowings KRW 30bn, cash and equivalents KRW 9.08bn, capital gearing ratio 17.5% – stable financial structure
Contingent liability: KRW 30bn guarantee for affiliate Hyorim E&A; lawsuit over choline alfoscerate refund agreement ongoing at appeal court
R&D expenditure KRW 1.76bn (4% of sales); pipelines include anti-inflammatory and anti-platelet new drugs
License-out deal with Rohto (Japan) for Levami eye drops (received USD 0.2mn) and other tech transfer agreements